Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen–mismatched donors

Brian Kornblit, Barry E. Storer, Niels S. Andersen, Michael B. Maris, Thomas R. Chauncey, Effie W. Petersdorf, Ann E. Woolfrey, Mary E. D. Flowers, Rainer Storb, David G. Maloney, Brenda M. Sandmaier

Blood (2020) 136 (13): 1499–1506.

https://doi.org/10.1182/blood.2020005338

Published: 2020

Includes: Supplemental data

Journal Articles

Sirolimus Combined with Mycophenolate Mofetil (MMF) and Cyclosporine (CSP) Significantly Improves Prevention of Acute Graft-Versus-Host-Disease (GVHD) after Unrelated Hematopoietic Cell Transplantation (HCT): Results from a Phase III Randomized Multi-Center Trial

Brenda M Sandmaier, MD, David G Maloney, MD PhD, Barry E. Storer, PhD, Gitte Olesen, MD, Michael B. Maris, MD, Jonathan A Gutman, MD, Soren Lykke Petersen, MD DMSC, Amelia Langston, MD, Thomas Chauncey, Wolfgang Bethge, MD, Michael A Pulsipher, MD, Brian Thomas Kornblit, MD PhD, Ann E Woolfrey, MD, Marco Mielcarek, MD, Paul J. Martin, MD, Mary E.D. Flowers, MD, Rainer F. Storb, MD

Blood (2016) 128 (22): 506.

https://doi.org/10.1182/blood.V128.22.506.506

Published: 2016

Journal Articles

Monitoring of Minimal Residual Disease before and after Allogeneic Stem Cell Transplantation Childhood ALL - a Retrospective Assessment on Behalf of the PDWP of the EBMT, the COG, PBMTC, the I-BFM and the Westhafen-Intercontinental-Group

Blood (2016) 128 (22): 985.

https://doi.org/10.1182/blood.V128.22.985.985

Published: 2016

Journal Articles

Gene Therapy for Fanconi Anemia in Seattle: Clinical Experience and Next Steps

Jennifer E Adair, PhD, Pamela S. Becker, MD PhD, Devikha Chandrasekaran, MSc, Grace Choi, BS, Ann E Woolfrey, MD, Lauri Burroughs, MD, Hans-Peter Kiem, MD FACP

Blood (2016) 128 (22): 3510.

https://doi.org/10.1182/blood.V128.22.3510.3510

Published: 2016

Journal Articles

The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy

Blood (2016) 127 (2): 260–267.

https://doi.org/10.1182/blood-2015-08-663823

Published: 2016

Journal Articles

5 Year Results of BMT CTN 0201: Unrelated Donor Bone Marrow Is Associated with Better Psychological Well-Being and Less Burdensome Chronic Gvhd Symptoms Than Peripheral Blood

Stephanie J. Lee, MD MPH, Brent Logan, PhD, Peter Westervelt, MD PhD, Corey S Cutler, MD MPH, Ann E Woolfrey, MD, Shakila Khan, MD, Edmund K Waller, MD PhD, Richard T. Maziarz, MD, Juan Wu, Bronwen E. Shaw, MBChB, PhD MRCP, MRCPath, Dennis L. Confer, MD, Mary M. Horowitz, MD MS, Claudio Anasetti, MD

Blood (2015) 126 (23): 270.

https://doi.org/10.1182/blood.V126.23.270.270

Published: 2015

Journal Articles

Minimal Residual Disease Does Not Impact Risk of Relapse in Myeloablative Umbilical Cord Blood Transplant Recipients: Comparison with Matched and Mismatched Unrelated Transplants

Filippo Milano, MD PhD, Ted A. Gooley, PhD, Brent L. Wood, MD PhD, Ann E Woolfrey, MD, Effie W. Petersdorf, MD, Frederick R. Appelbaum, MD, Colleen Delaney, MD MSC

Blood (2014) 124 (21): 2579.

https://doi.org/10.1182/blood.V124.21.2579.2579

Published: 2014

Journal Articles

Role of Comorbidities in Prognostic Evaluation of Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) from HLA-Mismatched (MM) and Umbilical Cord Blood (UCB) Donor Grafts

Mahmoud Elsawy, MD MSc, Barry E. Storer, PhD, Brenda M. Sandmaier, MD, Colleen Delaney, MD MSC, Frederick R. Appelbaum, MD, Ann E Woolfrey, MD, David G Maloney, MDPhD, Rainer F. Storb, MD, Mohamed L. Sorror, MD MSc

Blood (2014) 124 (21): 2583.

https://doi.org/10.1182/blood.V124.21.2583.2583

Published: 2014

Journal Articles

Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation

Blood (2014) 124 (16): 2596–2606.

https://doi.org/10.1182/blood-2014-05-576041

Published: 2014

Journal Articles

Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens

Blood (2014) 123 (10): 1615–1620.

https://doi.org/10.1182/blood-2013-10-535716

Published: 2014

Journal Articles

Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality

Blood (2013) 122 (22): 3651–3658.

https://doi.org/10.1182/blood-2013-05-501510

Published: 2013

Includes: Supplemental data

Journal Articles

Sorafenib Treatment Following Hematopoietic Stem Cell Transplant In Pediatric FLT3/ITD+ AML

Jessica Pollard, MD, Bill H Chang, MD, PhD, Todd Michael Cooper, Thomas Gross, MD, PhD, Sumit Gupta, MD, Phoenix A. Ho, MD, Suzanne M. McGoldrick, MD, Tanya C. Watt, MD, MSc, India Sisler, MD, Blythe Thomson, MD, Ann E Woolfrey, MD, Soheil Meshinchi, MD, PhD

Blood (2013) 122 (21): 3969.

https://doi.org/10.1182/blood.V122.21.3969.3969

Published: 2013

Journal Articles

Modulated Cyclophosphamide-Based In Vivo T-Cell Depletion Promotes Engraftment With Minimal Gvhd and Low Toxicity In Fanconi Anemia Patients

Monica S Thakar, MD, Mark C. Walters, MD, Brenda M. Sandmaier, MD, Rainer Storb, MD, Mary E. D. Flowers, MD, H. Joachim Deeg, MD, Paul O'Donnell, MD, PhD, Ann E. Woolfrey, MD, Hans-Peter Kiem, MD

Blood (2013) 122 (21): 4561.

https://doi.org/10.1182/blood.V122.21.4561.4561

Published: 2013

Journal Articles

The Outcome Of Allogeneic Hematopoietic Cell Transplantation In Children With FLT3/ITD-Positive Acute Myelogenous Leukemia

Tal Schechter, MD, Adam Gassas, MD, Heidi Chen, PhD, Jessica A. Pollard, MD, Soheil Meshinchi, MD, PhD, Zaidman Irina, MD, PhD, Johann K. Hitzler, MD, Mohamed M. Abdelhaleem, MD, PhD, FRCPC, Richard H. Ho, MD, MSCI, Jennifer Domm, MD, Ann E. Woolfrey, MD, Haydar A Frangoul, MD

Blood (2013) 122 (21): 2163.

https://doi.org/10.1182/blood.V122.21.2163.2163

Published: 2013

Journal Articles

Results Of a Phase I Study Of Clofarabine and 2 Gy Total Body Irradiation (TBI) As a Non-Myeloablative Preparative Regimen For Hematopoietic Stem Cell Transplantation (HSCT) In High Risk Children With Hematologic Malignancies: A Multi-Center TACL Study

Sandeep Soni, MD, Hisham Abdel-Azim, MD, Elena Eckroth, CCRC, Jeanette van der Geissen, BA, CCRP, Meghann Pine McManus, DO, MPH, Eneida R. Nemecek, MD, Richard Sposto, PhD, Blythe Thompson, MD, Ann E Woolfrey, MD, Haydar A Frangoul, MD

Blood (2013) 122 (21): 3286.

https://doi.org/10.1182/blood.V122.21.3286.3286

Published: 2013

Journal Articles

Results Of The Large Prospective Study On The Use Of Defibrotide (DF) In The Treatment Of Hepatic Veno-Occlusive Disease (VOD) In Hematopoietic Stem Cell Transplant (HSCT). Early Intervention Improves Outcome - Updated Results Of a Treatment IND (T-IND) Expanded Access Protocol

Blood (2013) 122 (21): 700.

https://doi.org/10.1182/blood.V122.21.700.700

Published: 2013

Journal Articles

Influence Of Killer Immunoglobulin-Like Receptor (KIR) and HLA Genotypes On Outcomes After Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation For Patients With AML and MDS: A Report From The Center For International Blood and Marrow Transplant Research Immunobiology Working Committee

Ronald M. Sobecks, MD, Meighan M. Gallagher, BA, Medhat Askar, MD, PhD, Michael D. Haagenson, MS, Tao Wang, PhD, Stephen Spellman, MBS, Stephanie J. Lee, MD, MPH, Marcelo A. Fernandez Viña, PhD, D(ABHI), Carlheinz R. Muller, MD, PhD, Michael R. Verneris, MD, Ann E. Woolfrey, MD, Peter J. Shaw, MD, Daniel J. Weisdorf, MD, Sarah Cooley, MD, Jeffrey S. Miller, MD, Katharine C. Hsu, MD, PhD

Blood (2013) 122 (21): 159.

https://doi.org/10.1182/blood.V122.21.159.159

Published: 2013

Journal Articles

A perspective on the selection of unrelated donors and cord blood units for transplantation

Stephen R. Spellman, Mary Eapen, Brent R. Logan, Carlheinz Mueller, Pablo Rubinstein, Michelle I. Setterholm, Ann E. Woolfrey, Mary M. Horowitz, Dennis L. Confer, Carolyn K. Hurley

Blood (2012) 120 (2): 259–265.

https://doi.org/10.1182/blood-2012-03-379032

Published: 2012

Journal Articles

Late effects among pediatric patients followed for nearly 4 decades after transplantation for severe aplastic anemia

Jean E. Sanders, Ann E. Woolfrey, Paul A. Carpenter, Barry E. Storer, Paul A. Hoffmeister, H. Joachim Deeg, Mary E. D. Flowers, Rainer F. Storb

Blood (2011) 118 (5): 1421–1428.

https://doi.org/10.1182/blood-2011-02-334953

Published: 2011

Journal Articles

Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood

Claudio G. Brunstein, Jonathan A. Gutman, Daniel J. Weisdorf, Ann E. Woolfrey, Todd E. DeFor, Theodore A. Gooley, Michael R. Verneris, Frederick R. Appelbaum, John E. Wagner, Colleen Delaney

Blood (2010) 116 (22): 4693–4699.

https://doi.org/10.1182/blood-2010-05-285304

Published: 2010

NARROW

Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen–mismatched donors

Sirolimus Combined with Mycophenolate Mofetil (MMF) and Cyclosporine (CSP) Significantly Improves Prevention of Acute Graft-Versus-Host-Disease (GVHD) after Unrelated Hematopoietic Cell Transplantation (HCT): Results from a Phase III Randomized Multi-Center Trial

Monitoring of Minimal Residual Disease before and after Allogeneic Stem Cell Transplantation Childhood ALL - a Retrospective Assessment on Behalf of the PDWP of the EBMT, the COG, PBMTC, the I-BFM and the Westhafen-Intercontinental-Group

Gene Therapy for Fanconi Anemia in Seattle: Clinical Experience and Next Steps

The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy

5 Year Results of BMT CTN 0201: Unrelated Donor Bone Marrow Is Associated with Better Psychological Well-Being and Less Burdensome Chronic Gvhd Symptoms Than Peripheral Blood

Minimal Residual Disease Does Not Impact Risk of Relapse in Myeloablative Umbilical Cord Blood Transplant Recipients: Comparison with Matched and Mismatched Unrelated Transplants

Role of Comorbidities in Prognostic Evaluation of Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) from HLA-Mismatched (MM) and Umbilical Cord Blood (UCB) Donor Grafts

Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation

Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens

Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality

Sorafenib Treatment Following Hematopoietic Stem Cell Transplant In Pediatric FLT3/ITD+ AML

Modulated Cyclophosphamide-Based In Vivo T-Cell Depletion Promotes Engraftment With Minimal Gvhd and Low Toxicity In Fanconi Anemia Patients

The Outcome Of Allogeneic Hematopoietic Cell Transplantation In Children With FLT3/ITD-Positive Acute Myelogenous Leukemia

Results Of a Phase I Study Of Clofarabine and 2 Gy Total Body Irradiation (TBI) As a Non-Myeloablative Preparative Regimen For Hematopoietic Stem Cell Transplantation (HSCT) In High Risk Children With Hematologic Malignancies: A Multi-Center TACL Study

Results Of The Large Prospective Study On The Use Of Defibrotide (DF) In The Treatment Of Hepatic Veno-Occlusive Disease (VOD) In Hematopoietic Stem Cell Transplant (HSCT). Early Intervention Improves Outcome - Updated Results Of a Treatment IND (T-IND) Expanded Access Protocol

A perspective on the selection of unrelated donors and cord blood units for transplantation

Late effects among pediatric patients followed for nearly 4 decades after transplantation for severe aplastic anemia

Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only